UBE, SANTEEN TO DEVELOP DE-104
Japan-based Ube Industries and Santen Pharmaceutical have entered into an agreement to develop DE-104, a compound that inhibits the activity of Rho-kinase (ROCK).
Through the collaboration, the companies aim to develop an ophthalmic solution for treating glaucoma and ocular hypertension. ROCK is an enzyme that phosphorylates cytoskeletal regulatory proteins and plays a role in cytoskeletal regulation.
Details of the collaboration project have not yet been determined.